Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?

Molecular Neurobiology

Volumn 52, Issue 3, 2015, Pages 1297-1314

  Hoffner, Guylaine ^a   Djian, Philippe ^a  

^a CNRS   (France)

Author keywords

Amyloid; Fibrils; Huntingtin; Inclusions; Oligomers; Sheets

Indexed keywords

ASPARTIC PROTEINASE; CALPAIN; CASPASE 3; CASPASE 6; CONGO RED; HUNTINGTIN; OLIGOMER; POLYGLUTAMINE; AMYLOID; EPITOPE; HTT PROTEIN, HUMAN; NERVE PROTEIN; PEPTIDE; PEPTIDE FRAGMENT; PEPTIDE HYDROLASE; PROTEIN AGGREGATE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BETA SHEET; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CYTOTOXICITY; EXON; HUMAN; HUNTINGTON CHOREA; NONHUMAN; NUCLEATED GROWTH POLYMERIZATION; NUCLEATION DEPENDENT POLYMERIZATION; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; X RAY DIFFRACTION; ANIMAL; BIREFRINGENCE; BRAIN; CELL INCLUSION; CHEMICAL STRUCTURE; CHEMISTRY; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TRANSPORT; PROTEINOSIS; RAT; SOLUBILITY; STRUCTURE ACTIVITY RELATION; TRANSGENIC ANIMAL; ULTRASTRUCTURE;

AMYLOID; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIREFRINGENCE; BRAIN; EPITOPES; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; MICE; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PEPTIDES; POLYMERIZATION; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN TRANSPORT; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 84942832983     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8932-1     Document Type: Review

References (150)

1. Hoffner G, Djian P (2002) Protein aggregation in Huntington’s disease. Biochimie 84:273–278
2. Margulis BA, Vigont V, Lazarev VF, Kaznacheyeva EV, Guzhova IV (2013) Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors. FEBS Lett 587:1997–2007
3. The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983
4. Green H, Djian P (1998) Amino acid repeats in proteins and the neurological diseases produced by polyglutamine. In: Wells R, Warren S (eds) Genetic Instabilities and Hereditary Neurological Diseases. Academic Press, New York, pp 739–759
5. Perutz M, Johnson T, Suzuki M, Finch J (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91:5355–5358
6. Davies S, Turmaine M, Cozens B et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548
7. DiFiglia M, Sapp E, Chase K et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993
8. Saudou F, Finkbeiner S, Devys D, Greenberg M (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55–66
9. Arrasate M, Mitra S, Schweitzer E, Segal M, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810
10. Klement IA, Skinner PJ, Kaytor MD et al (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41–53
11. Perutz MF (1999) Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci 24:58–63
12. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM (1999) Huntington’s disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156:92–99
13. Iuchi S, Hoffner G, Verbeke P, Djian P, Green H (2003) Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci U S A 100:2409–2414
14. Hoffner G, Island M, Djian P (2005) Purification of neuronal inclusions of patients with Huntington’s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem 95:125–136
15. Lunkes A, Lindenberg KS, Ben-Haïem L et al (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10:259–269
16. Zhou H, Cao F, Wang Z et al (2003) Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol 163:109–118
17. Goldberg YP, Nicholson DW, Rasper DM et al (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13:442–449
18. Kim YJ, Yi Y, Sapp E et al (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington’s disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci U S A 98:12784–12789
19. Gafni J, Ellerby LM (2002) Calpain activation in Huntington’s disease. J Neurosci 22:4842–4849
20. Wellington CL, Ellerby LM, Gutekunst CA et al (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington’s disease. J Neurosci 22:7862–7872
21. Southwell AL, Bugg CW, Kaltenbach LS et al (2011) Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS One 6:e16676
22. Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 110:2366–2370
23. Wheeler VC, White JK, Gutekunst CA et al (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9:503–513
24. Cooper JK, Schilling G, Peters MF et al (1998) Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7:783–790
25. Cornett J, Cao F, Wang CE et al (2005) Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 37:198–204
26. Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506
27. Morton AJ, Glynn D, Leavens W et al (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 33:331–341
28. Dragatsis I, Goldowitz D, Del Mar N et al (2009) CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington’s disease transgenic mouse. Neurobiol Dis 33:315–330
29. Havel LS, Wang CE, Wade B, Huang B, Li S, Li XJ (2011) Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet 20:1424–1437
30. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233–238
31. Martindale D, Hackam A, Wieczorek A et al (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18:150–154
32. Wang CE, Tydlacka S, Orr AL et al (2008) Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington’s disease. Hum Mol Genet 17:2738–2751
33. Chan AW, Cheng PH, Neumann A, Yang JJ (2010) Reprogramming Huntington monkey skin cells into pluripotent stem cells. Cell Reprogram 12:509–517
34. Castiglioni V, Onorati M, Rochon C, Cattaneo E (2012) Induced pluripotent stem cell lines from Huntington’s disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Neurobiol Dis 46:30–40
35. Camnasio S, Delli Carri A, Lombardo A et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 46:41–51
36. Consortium Hi (2012) Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264–278
37. Juopperi TA, Kim WR, Chiang CH et al (2012) Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells. Mol Brain 5:17
38. Scherzinger E, Lurz R, Turmaine M et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549–558
39. Tanaka M, Morishima I, Akagi T, Hashikawa T, Nukina N (2001) Intra- and intermolecular β-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem 276:45470–45475
40. Chen S, Berthelier V, Hamilton J, O’Nuallain B, Wetzel R (2002) Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41:7391–7399
41. Trottier Y, Lutz Y, Stevanin G et al (1995) Polyglutamine expansion as a pathological epitope in Huntington’s disease and four dominant cerebellar ataxias. Nature 378:403–406
42. Huang CC, Faber PW, Persichetti F et al (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 24:217–233
43. Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Ross SA, Bjorkman PJ (2002) A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A 99:11634–11639
44. Li P, Huey-Tubman KE, Gao T et al (2007) The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat Struct Mol Biol 14:381–387
45. Klein FA, Zeder-Lutz G, Cousido-Siah A et al (2013) Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10. Hum Mol Genet 22:4215–4223
46. Peters-Libeu C, Miller J, Rutenber E et al (2012) Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure. J Mol Biol 421:587–600
47. Masino L, Kelly G, Leonard K, Trottier Y, Pastore A (2002) Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett 513:267–272
48. Klein FA, Pastore A, Masino L et al (2007) Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J Mol Biol 371:235–244
49. Nagai Y, Inui T, Popiel HA et al (2007) A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 14:332–340
50. Nagai Y, Tucker T, Ren H et al (2000) Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J Biol Chem 275:10437–10442
51. Kim M, Chelliah Y, Kim S, Otwinowski Z, Bezprozvanny I (2009) Secondary structure of Huntingtin amino-terminal region. Structure 17:1205–1212
52. Perutz M, Windle A (2001) Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412:143–144
53. Sipe JD, Benson MD, Buxbaum JN et al (2012) Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19:167–170
54. McGowan DP, van Roon-Mom W, Holloway H et al (2000) Amyloid-like inclusions in Huntington’s disease. Neuroscience 100:677–680
55. Astbury WT, Dickinson S, Bailey K (1935) The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem J 29:2351–2360.2351
56. Tycko R, Wickner RB (2013) Molecular structures of amyloid and prion fibrils: consensus versus controversy. Acc Chem Res 46:1487–1496
57. Eanes ED, Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16:673–677
58. Bonar L, Cohen AS, Skinner MM (1969) Characterization of the amyloid fibril as a cross-βprotein. Proc Soc Exp Biol Med 131:1373–1375
59. Perutz MF, Finch JT, Berriman J, Lesk A (2002) Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci U S A 99:5591–5595
60. Benhold H (1922) Eine spezifische Amyloidfarbung mit Kongorot. Muenchen Med Wochenschr 69:1537–1538
61. Divry P (1927) Etude histochimique des plaques séniles. Journal Belge de Neurologie et de Psychiatrie 27:643–657
62. Missmahl H, Hartig M (1953) Polarisations optische Untersuchungen an der Amyloidsubstanz. Virchow Arch Path Anat 324:489–508
63. Wu C, Wang Z, Lei H, Zhang W, Duan Y (2007) Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations. J Am Chem Soc 129:1225–1232
64. Frid P, Anisimov SV, Popovic N (2007) Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev 53:135–160
65. Schütz AK, Soragni A, Hornemann S et al (2011) The amyloid-Congo red interface at atomic resolution. Angew Chem Int Ed Engl 50:5956–5960
66. Klunk WE, Pettegrew JW, Abraham DJ (1989) Quantitative evaluation of congo red binding to amyloid-like proteins with a β-pleated sheet conformation. J Histochem Cytochem 37:1273–1281
67. Carter DB, Chou KC (1998) A model for structure-dependent binding of Congo red to Alzheimer β-amyloid fibrils. Neurobiol Aging 19:37–40
68. Steffan JS, Kazantsev A, Spasic-Boskovic O et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97:6763–6768
69. Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 153:283–294
70. Wanderer J, Morton AJ (2007) Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington’s disease. Histochem Cell Biol 127:473–484
71. Hoffner G, André W, Vanhoutteghem A, Souès S, Djian P (2010) Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition. CNS Neurol Disord Drug Targets 9:217–231
72. Heiser V, Scherzinger E, Boeddrich A et al (2000) Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington’s disease therapy. Proc Natl Acad Sci U S A 97:6739–6744
73. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA (2002) Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 277:41032–41037
74. Apostol BL, Kazantsev A, Raffioni S et al (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A 100:5950–5955
75. Smith DL, Portier R, Woodman B et al (2001) Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose–response profiles. Neurobiol Dis 8:1017–1026
76. Benzinger TL, Gregory DM, Burkoth TS et al (1998) Propagating structure of Alzheimer’s β-amyloid(10–35) is parallel β-sheet with residues in exact register. Proc Natl Acad Sci U S A 95:13407–13412
77. Qiang W, Yau WM, Luo Y, Mattson MP, Tycko R (2012) Antiparallel β-sheet architecture in Iowa-mutant β-amyloid fibrils. Proc Natl Acad Sci U S A 109:4443–4448
78. Sikorski P, Atkins E (2005) New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 6:425–432
79. Schneider R, Schumacher MC, Mueller H et al (2011) Structural characterization of polyglutamine fibrils by solid-state NMR spectroscopy. J Mol Biol 412:121–136
80. Sivanandam VN, Jayaraman M, Hoop CL, Kodali R, Wetzel R, van der Wel PC (2011) The aggregation-enhancing huntingtin N-terminus is helical in amyloid fibrils. J Am Chem Soc 133:4558–4566
81. Sharma D, Shinchuk LM, Inouye H, Wetzel R, Kirschner DA (2005) Polyglutamine homopolymers having 8–45 residues form slablike β-crystallite assemblies. Proteins 61:398–411
82. Thakur AK, Wetzel R (2002) Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci U S A 99:17014–17019
83. Zhang QC, Yeh TL, Leyva A et al (2011) A compact β model of huntingtin toxicity. J Biol Chem 286:8188–8196
84. Poirier MA, Jiang H, Ross CA (2005) A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact β-sheet structure. Hum Mol Genet 14:765–774
85. Bevivino AE, Loll PJ (2001) An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel β-fibrils. Proc Natl Acad Sci U S A 98:11955–11960
86. Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O (2008) Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet 17:345–356
87. André W, Sandt C, Dumas P, Djian P, Hoffner G (2013) Structure of inclusions of Huntington’s disease brain revealed by synchrotron infrared microspectroscopy: polymorphism and relevance to cytotoxicity. Anal Chem 85:3765–3773
88. Harper JD, Lansbury PT (1997) Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66:385–407
89. Wetzel R (2012) Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol 421:466–490
90. Clarke G, Collins RA, Leavitt BR et al (2000) A one-hit model of cell death in inherited neuronal degenerations. Nature 406:195–199
91. Vonsattel J, Myers R, Stevens T, Ferrante R, Bird E, Richardson EJ (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577
92. Chen S, Ferrone FA, Wetzel R (2002) Huntington’s disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A 99:11884–11889
93. Kar K, Jayaraman M, Sahoo B, Kodali R, Wetzel R (2011) Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent. Nat Struct Mol Biol 18:328–336
94. Gupta S, Jie S, Colby DW (2012) Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay. J Biol Chem 287:9982–9989
95. Tonoki A, Kuranaga E, Ito N, Nekooki-Machida Y, Tanaka M, Miura M (2011) Aging causes distinct characteristics of polyglutamine amyloids in vivo. Genes Cells 16:557–564
96. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, Tanaka M (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci U S A 106:9679–9684
97. Furukawa Y, Kaneko K, Matsumoto G, Kurosawa M, Nukina N (2009) Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci 29:5153–5162
98. Rockabrand E, Slepko N, Pantalone A et al (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16:61–77
99. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103:11045–11050
100. Bhattacharyya A, Thakur AK, Chellgren VM et al (2006) Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol 355:524–535
101. Dehay B, Bertolotti A (2006) Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem 281:35608–35615
102. Ignatova Z, Thakur AK, Wetzel R, Gierasch LM (2007) In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence. J Biol Chem 282:36736–36743
103. Ratovitski T, Gucek M, Jiang H et al (2009) Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284:10855–10867
104. Tam S, Spiess C, Auyeung W et al (2009) The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 16:1279–1285
105. Thakur A, Jayaraman M, Mishra R et al (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16:380–389
106. Lee CC, Walters RH, Murphy RM (2007) Reconsidering the mechanism of polyglutamine peptide aggregation. Biochemistry 46:12810–12820
107. Jayaraman M, Kodali R, Sahoo B et al (2012) Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J Mol Biol 415:881–899
108. Mishra R, Jayaraman M, Roland BP et al (2012) Inhibiting the nucleation of amyloid structure in a huntingtin fragment by targeting α-helix-rich oligomeric intermediates. J Mol Biol 415:900–917
109. Tam S, Geller R, Spiess C, Frydman J (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8:1155–1162
110. Liebman SW, Meredith SC (2010) Protein folding: sticky N17 speeds huntingtin pile-up. Nat Chem Biol 6:7–8
111. Fiumara F, Fioriti L, Kandel ER, Hendrickson WA (2010) Essential role of coiled coils for aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell 143:1121–1135
112. Legleiter J, Mitchell E, Lotz G et al (2010) Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285:14777–14790
113. Pennuto M, Palazzolo I, Poletti A (2009) Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum Mol Genet 18:R40–47
114. Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17:475–492
115. Tsai YC, Fishman PS, Thakor NV, Oyler GA (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 278:22044–22055
116. Steffan J, Agrawal N, Pallos J et al (2004) SUMO modification of Huntingtin and Huntington’s disease pathology. Science 304:100–104
117. Thompson LM, Aiken CT, Kaltenbach LS et al (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 187:1083–1099
118. Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182–6195
119. Gu X, Greiner ER, Mishra R et al (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64:828–840
120. Mishra R, Hoop CL, Kodali R, Sahoo B, van der Wel PC, Wetzel R (2012) Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. J Mol Biol 424:1–14
121. Atwal RS, Desmond CR, Caron N et al (2011) Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 7:453–460
122. Arnesen T, Starheim KK, Van Damme P et al (2010) The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation. Mol Cell Biol 30:1898–1909
123. Darnell GD, Derryberry J, Kurutz JW, Meredith SC (2009) Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect. Biophys J 97:2295–2305
124. Lakhani VV, Ding F, Dokholyan NV (2010) Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences. PLoS Comput Biol 6:e1000772
125. Li M, Chevalier-Larsen ES, Merry DE, Diamond MI (2007) Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem 282:3157–3164
126. Legleiter J, Lotz GP, Miller J et al (2009) Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem 284:21647–21658
127. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ (2004) Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 11:1215–1222
128. Takahashi Y, Okamoto Y, Popiel HA et al (2007) Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol Chem 282:24039–24048
129. Weiss A, Klein C, Woodman B et al (2008) Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease. J Neurochem 104:846–858
130. Olshina MA, Angley LM, Ramdzan YM et al (2010) Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem 285:21807–21816
131. Nucifora LG, Burke KA, Feng X et al (2012) Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem 287:16017–16028
132. Sathasivam K, Lane A, Legleiter J et al (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington’s disease. Hum Mol Genet 19:65–78
133. Baldo B, Paganetti P, Grueninger S et al (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington’s disease. Chem Biol 19:264–275
134. Marcellin D, Abramowski D, Young D et al (2012) Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. PLoS One 7:e44457
135. Kahlem P, Green H, Djian P (1998) Transglutaminase action imitates Huntington’s disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1:595–601
136. Ross C, Poirier M, Wanker E, Amzel M (2003) Polyglutamine fibrillogenesis: the pathway unfolds. Proc Natl Acad Sci U S A 100:1–3
137. Tanaka M, Machida Y, Nishikawa Y et al (2003) Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. J Biol Chem 278:34717–34724
138. Lansbury PT (1997) Structural neurology: are seeds at the root of neuronal degeneration? Neuron 19:1151–1154
139. McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Αβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866
140. Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid βprotein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539
141. Nagai Y, Fujikake N, Ohno K et al (2003) Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum Mol Genet 12:1253–1259
142. Popiel HA, Takeuchi T, Burke JR et al (2013) Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases. Neurotherapeutics 10:440–446
143. Ehrnhoefer DE, Duennwald M, Markovic P et al (2006) Green tea (−)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet 15:2743–2751
144. Slow EJ, Graham RK, Osmand AP et al (2005) Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A 102:11402–11407
145. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 97:7841–7846
146. Susi H, Byler DM (1983) Protein structure by Fourier transform infrared spectroscopy: second derivative spectra. Biochem Biophys Res Commun 115:391–397
147. Jackson M, Mantsch HH (1995) The use and misuse of FTIR spectroscopy in the determination of protein structure. Crit Rev Biochem Mol Biol 30:95–120
148. Barth A (2007) Infrared spectroscopy of proteins. Biochim Biophys Acta 1767:1073–1101
149. Zandomeneghi G, Krebs M, McCammon M, Fändrich M (2004) FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein Sci 13:3314–3321
150. Hiramatsu H, Kitagawa T (2005) FT-IR approaches on amyloid fibril structure. Biochim Biophys Acta 1753:100–107